Can you lose weight on Wegovy's starting dose of 0.25 mg?

You've just started 0.25 mg, here's what's actually happening

Picture the moment: your DPD parcel arrives, plain and unbranded, you open it to find the Wegovy pen, and you wonder whether this small starting dose is actually doing anything. That curiosity is reasonable. The 0.25 mg pen exists for one specific reason, it gives your gut time to adapt to semaglutide before the dose climbs. GLP-1 receptor agonists slow gastric emptying and reduce appetite, and introducing them too quickly causes the nausea and vomiting that prompt people to give up. The first four weeks are about tolerability, not transformation.

That said, the hormone pathway is already active at 0.25 mg. Some people report a noticeable reduction in hunger within the first week; a smaller number see a modest drop on the scale. Both responses are normal, and neither predicts how you will respond at higher doses. If you feel almost nothing at this stage, that is equally normal. The medicine is not failing, it is still in its settling-in phase.

The NHS patient information page for semaglutide explains the step-up schedule clearly and is worth reading alongside the patient information leaflet that comes with your pen. Questions about timing or what you are experiencing belong with your prescriber, not a search engine.

When the meaningful weight loss tends to begin

The trial data anchors expectations firmly. In the STEP 1 study (68 weeks, adults with obesity and no diabetes, semaglutide 2.4 mg against placebo) average body weight fell by roughly 15%, with participants losing the bulk of that weight during and after the titration phase rather than at the outset. At the maintenance dose, appetite suppression and the slowing of gastric emptying work together in a sustained way that a sub-therapeutic starter dose simply cannot replicate.

You can read the STEP 1 trial in the New England Journal of Medicine for the full dataset. What it shows, practically, is that patience through the titration schedule pays off. Trying to hold at 0.25 mg indefinitely in the hope of avoiding side effects would mean missing most of the treatment's benefit. Your prescriber decides the right pace, typically a step up every four weeks, subject to how you are tolerating each level.

There is also a useful question worth asking yourself at this stage: are you eating differently because your appetite genuinely feels different, or are you trying to compensate through willpower? GLP-1 medicines reduce hunger signals, the goal is for eating less to feel natural rather than effortful. If that shift is not yet happening, it is more likely to emerge at a higher dose than to stay absent forever. Our overview of the full Wegovy dose schedule sets out what each step looks like.

What makes some people more likely to see early results

There is genuine individual variation in early response. Factors that seem to influence it include baseline weight, how consistently the weekly injection is timed, and the degree to which dietary habits shift alongside treatment. The medicine is licensed alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention. People who make those adjustments from week one tend to see them compound as the dose rises.

It is also worth knowing that some patients transfer to Wegovy from another GLP-1 medicine and arrive already tolerant of the drug class, which means 0.25 mg can feel almost imperceptible to them. That is different from starting fresh. If you are curious about how earlier doses compare in practice, the detail behind 0.25 mg effectiveness and weight loss at low Wegovy doses generally covers more of the evidence in those specific contexts.

One note that a question our prescribers hear regularly: "Should I stay on 0.25 mg longer to be safe?" The honest answer is that the tolerability dose is not intrinsically safer than the next step for most people, it is just the prescribed starting point. Moving up is part of the plan, not a risk to avoid. Your prescriber's job is to assess that with you at each review.

The cost of starting treatment and what clinical support looks like

Wegovy is a private prescription outside the NHS specialist pathway, and the price varies by dose and provider. Our Wegovy cost guide gives transparent context on what UK private treatment typically involves and what a legitimate quote should include. A prescription alone is not enough, ongoing clinical review matters as much as the first pen, particularly when dose increases require assessment.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. There are no automated approvals. If you have questions once treatment is underway, aftercare support is available seven days a week. For a fuller picture of what Wegovy treatment involves from the first pen onwards, the Wegovy treatment page covers the whole journey. When you are ready to check whether you meet the clinical criteria, checking your eligibility takes a few minutes and costs nothing.